Importance of hematocrit for a tacrolimus target concentration strategy

European Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2014, Pages 65-77

  Størset, Elisabet ^a,b   Holford, Nick ^c   Midtvedt, Karsten ^a   Bremer, Sara ^a   Bergan, Stein ^a   Åsberg, Anders ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Fat free mass; Hematocrit; Kidney transplantation; Population pharmacokinetics; Tacrolimus; Target concentration intervention

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADULT; AGED; ARTICLE; BODY SIZE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FAT FREE MASS; FEMALE; HEMATOCRIT; HUMAN; KIDNEY GRAFT; MALE; MIDDLE AGED; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TACROLIMUS; YOUNG ADULT;

EID: 84891867528     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1584-7     Document Type: Article

References (45)

1. Wallemacq P, Armstrong VW, Brunet M et al (2009) Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31(2):139-152
2. Bouamar R, Shuker N, Hesselink DA et al (2013) Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am J Transplant 13:1253-1261. doi: 10.1111/ajt.12191
3. Barraclough KA, Isbel NM, Kirkpatrick CM et al (2011) Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 71:207-223. doi: 10.1111/j.1365-2125. 2010.03815.x
4. Scholten EM, Cremers SC, Schoemaker RC et al (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67:2440-2447. doi: 10.1111/j.1523-1755.2005.00352.x (Pubitemid 41623408)
5. Saint-Marcoux F, Woillard J-B, Jurado C, Marquet P (2013) Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit 35:322-327. doi: 10.1097/FTD.0b013e318285e779
6. Ekberg H, Mamelok RD, Pearson TC et al (2009) The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony Study. Transplantation 87:1360-1366. doi: 10.1097/TP.0b013e3181a23cb2
7. Jusko WJ, Piekoszewski W, Klintmalm GB et al (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57:281-290. doi: 10.1016/0009-9236(95)90153-1
8. Zahir H, McCaughan G, Gleeson M et al (2004) Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 57:298-309 (Pubitemid 38296993)
9. Hebert MF, Zheng S, Hays K et al (2013) Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation 95:908-915. doi: 10.1097/TP.0b013e318278d367
10. Möller A, Iwasaki K, Kawamura A et al (1999) The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 27:633-636 (Pubitemid 29252435)
11. Malyszko J, Oberbauer R, Watschinger B (2012) Anemia and Erythrocytosis in patients after kidney transplantation. Transpl Int 25:1013-1023. doi: 10.1111/j.1432-2277.2012.01513.x
12. Falck P, Vethe NT, Åsberg A et al (2008) Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 23:1048-1053. doi: 10.1093/ndt/gfm632 (Pubitemid 351767545)
13. Amundsen R, Åsberg A, Robertsen I et al (2009) Rimonabant affects cyclosporine A, but not tacrolimus pharmacokinetics in renal transplant recipients. Transplantation 87:1221-1224. doi: 10.1097/TP.0b013e31819f1001
14. Midtvedt K, Jenssen T, Hartmann A et al (2011) No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant 26:3767-3772. doi: 10.1093/ndt/gfr153
15. Marubashi S, Nagano H, Kobayashi S et al (2010) Evaluation of a new immunoassay for therapeutic drug monitoring of tacrolimus in adult liver transplant recipients. J Clin Pharmacol 50:705-709. doi: 10.1177/ 0091270009352188
16. Falck P, Åsberg A, Byberg KT et al (2008) Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation 86:1379-1383. doi: 10.1097/TP.0b013e31818aa4b6
17. Cheung CY, Op den Buijsch RA, Wong KM et al (2006) Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 7:563-574. doi: 10.2217/14622416.7.4.563 (Pubitemid 43891413)
18. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735-750 (Pubitemid 24052760)
19. Kerbusch T, Wahlby U, Milligan PA, Karlsson MO (2003) Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 56:639-652 (Pubitemid 37491716)
20. Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25-36
21. Janmahasatian S, Duffull SB, Ash S et al (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065 (Pubitemid 41356391)
22. Størset E, Staatz C, Hennig S, et al (2013) Identification of continuous covariate relationships. Presented at the annual meeting of Population Approach Group of Australia and New Zealand (PAGANZ). Available at: http://www.paganz.org/abstracts/identification-of-continuous-covariate- relationships
23. Beal SL, Sheiner LB, Boeckmann AJ (1989-2006) NONMEM user's guides. Icon Development Solutions, Ellicott City, MD
24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143-151. doi: 10.1208/s12248-011-9255-z
25. Wahlby U, Jonsson EN, Karlsson MO (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4:E27. doi: 10.1208/ps040427
26. Efron B (1979) Bootstrap methods: another look at the jackknife. Ann Stat 7:1-26
27. Holford NHG (2011) Wings for NONMEM, v. 720 for NONMEM 7.2. Available at: http://wfn.sourceforge.net
28. Han N, Yun HY, Hong JY et al (2012) Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. doi: 10.1007/s00228-012-1296-4
29. Woillard JB, de Winter BC, Kamar N et al (2011) Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol 71:391-402. doi: 10.1111/j.1365-2125.2010.03837.x
30. Benkali K, Premaud A, Picard N et al (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48:805-816. doi: 10.2165/11318080- 000000000-00000
31. de Jonge H, de Loor H, Verbeke K et al (2012) In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 92:366-375. doi: 10.1038/clpt.2012.109
32. Musuamba FTF, Mourad MM, Haufroid VV et al (2012) A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol 52:1833-1843. doi: 10.1177/0091270011423661
33. Reidenberg MM, Odar-Cederlöf I, von Bahr C et al (1971) Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 285:264-267. doi: 10.1056/ NEJM197107292850506
34. Musteata FM (2012) Calculation of normalized drug concentrations in the presence of altered plasma protein binding. Clin Pharmacokinet 51:55-68. doi: 10.2165/11595650-000000000-00000
35. Press RR, Ploeger BA, den Hartigh J et al (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 31:187-197. doi: 10.1097/FTD. 0b013e31819c3d6d
36. Rodrigo E, de Cos MA, Sanchez B et al (2005) High initial blood levels of tacrolimus in overweight renal transplant recipients. Transplant Proc 37:1453-1454. doi: 10.1016/j.transproceed.2005.02.055 (Pubitemid 40712079)
37. Stratta P, Quaglia M, Cena T et al (2012) The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol 68:671-680. doi: 10.1007/s00228-011-1150-0
38. Kuypers DR, Claes K, Evenepoel P et al (2004) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43:741-762 (Pubitemid 39159005)
39. Antignac M, Barrou B, Farinotti R et al (2007) Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 64:750-757. doi: 10.1111/j.1365-2125.2007.02895.x (Pubitemid 350222052)
40. Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33-60 (Pubitemid 40100551)
41. Jacobson PA, Schladt D, Oetting WS et al (2012) Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant 12:3326-3336. doi: 10.1111/j.1600-6143.2012. 04232.x
42. Passey C, Birnbaum AK, Brundage RC et al (2011) Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 72:948-957. doi: 10.1111/j.1365-2125.2011.04039.x
43. Tomita T, Homma M, Hasegawa Y et al (2008) Use of sample hematocrit value to correct blood tacrolimus concentration derived by microparticle enzyme immunoassay. Biol Pharm Bull 31:1250-1253 (Pubitemid 351871192)
44. Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562-2575. doi: 10.1056/NEJMoa067411 (Pubitemid 350294223)
45. Schiff J, Cole E, Cantarovich M (2007) Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2:374-384. doi: 10.2215/CJN.03791106